The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Advances in the Treatment of Alzheimer’s Disease: Benefits of Dual Cholinesterase Inhibition
Abstract
Cholinesterase inhibitors have produced the best evidence of clinical efficacy for treating patients with Alzheimer’s disease (AD). Many of these drugs selectively inhibit acetylcholinesterase (AChE), but agents that also target butyrylcholinesterase (BuChE) may provide added benefits. As AD progresses, ACh regulation may become increasingly dependent on BuChE and dual inhibitors may provide more sustained efficacy than AChE-selective agents. Dual inhibition may also help to slow the formation of amyloidogenic compounds, providing an important disease-modifying mechanism. Rivastigmine is a dual inhibitor that has demonstrated benefits across the spectrum of AD severity and across the cognitive, functional and behavioural domains of AD. It is a priority for future clinical trials to determine whether agents with dual inhibition properties have greater clinical efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The cholinergic hypothesis of geriatric memory dysfunction
Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545
Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain
Whitehouse, P., Price, D., Struble, R., Clark, A., Coyle, J., & DeLong, M. R. (1982) · Science · doi:10.1126/science.7058341 · Cited by 3,627
SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565
Doody, R. S., Stevens, J. C., Beck, C., Dubinsky, R. M., Kaye, J. A., Gwyther, L., Mohs, R. C., Thal, L. J., Whitehouse, P. J., DeKosky, S. T., et al. (2001) · Neurology · doi:10.1212/wnl.56.9.1154 · Cited by 1,720
McKeith, I., Del Ser, T., Spano, P., Emre, M., Wesnes, K., Anand, R., Cicin-Sain, A., Ferrara, R., & Spiegel, R. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03399-7 · Cited by 1,182
Lyketsos, C. G., Steinberg, M., Tschanz, J. T., Norton, M. C., Steffens, D. C., & Breitner, J. C. S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.5.708 · Cited by 1,144
Inestrosa, N. C., Alvarez, A., Pérez, C. A., Moreno, R. D., Vicente, M., Linker, C., Casanueva, O. I., Soto, C., & Garrido, J. (1996) · Neuron · doi:10.1016/s0896-6273(00)80108-7 · Cited by 1,101
Acetylcholinesterase: Enzyme structure, reaction dynamics, and virtual transition states
Quinn, D. M. (1987) · Chemical Reviews · doi:10.1021/cr00081a005 · Cited by 1,072 · cited 1×
“Once in the gorge of either enzyme, ACh is cleaved and its neurotransmitter action is terminated [”
BackgroundRosler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal-Bianco, P., Stahelin, H. B., Hartman, R., Gharabawi, M., & Bayer, T. (1999) · BMJ · doi:10.1136/bmj.318.7184.633 · Cited by 943
The Cholinesterases: From Genes to Proteins
Taylor, P., & Radic, Z. (1994) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.34.040194.001433 · Cited by 669
Neurotransmitter-related enzymes in senile dementia of the alzheimer type
Davies, P. (1979) · Brain Research · doi:10.1016/0006-8993(79)90336-6 · Cited by 634
CHANGES IN BRAIN CHOLINESTERASES IN SENILE DEMENTIA OF ALZHEIMER TYPE
PERRY, E. K., PERRY, R. H., BLESSED, G., & TOMLINSON, B. E. (1978) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.1978.tb00545.x · Cited by 555
Jeste, D. V., Alexopoulos, G. S., Bartels, S. J., Cummings, J. L., Gallo, J. J., Gottlieb, G. L., Halpain, M. C., Palmer, B. W., Patterson, T. L., Reynolds, C. F., et al. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.9.848 · Cited by 521
Corey-Bloom, J. (1998) · Medical Entomology and Zoology · Cited by 467
The cholinergic system in Alzheimer's disease
Kása, P., Rakonczay, Z., & Gulya, K. (1997) · Progress in Neurobiology · doi:10.1016/s0301-0082(97)00028-2 · Cited by 409
Cholinesterase Inhibitors: A New Class of Psychotropic Compounds
Cummings, J. L. (2000) · American Journal of Psychiatry · doi:10.1176/ajp.157.1.4 · Cited by 384
Li, B., Stribley, J. A., Ticu, A., Xie, W., Schopfer, L. M., Hammond, P., Brimijoin, S., Hinrichs, S. H., & Lockridge, O. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.751320.x · Cited by 354
Practice parameter: Management of dementia (an evidence-based review)
Oken, B. S. (2001) · Neurology · doi:10.1212/wnl.57.12.2323 · Cited by 351
Ritchie, K., & Kildea, D. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91556-7 · Cited by 340
Farlow, M., Anand, R., Messina Jr, J., Hartman, R., & Veach, J. (2000) · European Neurology · doi:10.1159/000008243 · Cited by 332 · cited 1×
“Another study evaluating the long-term dual inhibitory effects of rivastigmine showed that the target enzymes were inhibited in the CSF and, to a lesser extent, the plasma compartment for at least 12 months (unpublished data).Rivastigmine has demonstrated broad, sustained benefits in patients with AD or dementia with…”
BackgroundArendt, T., Brückner, M. K., Lange, M., & Bigl, V. (1992) · Neurochemistry International · doi:10.1016/0197-0186(92)90189-x · Cited by 314
Butyrylcholinesterase in the life cycle of amyloid plaques
Guillozet, A. L., Mesulam, M. ‐., Smiley, J. F., & Mash, D. C. (1997) · Annals of Neurology · doi:10.1002/ana.410420613 · Cited by 310
Weinstock, M. (1999) · CNS Drugs · doi:10.2165/00023210-199912040-00005 · Cited by 278
Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia
Mesulam, ‐., & Geula, C. (1994) · Annals of Neurology · doi:10.1002/ana.410360506 · Cited by 258
Xie, W., Stribley, J. A., Chatonnet, A., Wilder, P. J., Rizzino, A., McComb, R. D., Taylor, P., Hinrichs, S. H., & Lockridge, O. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39312-7 · Cited by 255
Bryant, J., Clegg, A., Nicholson, T., McIntyre, L., De Broe, S., Gerard, K., & Waugh, N. (2001) · Health Technology Assessment · doi:10.3310/hta5010 · Cited by 246
Wright, C. I., Geula, C., & Mesulam, M. ‐. (1993) · Annals of Neurology · doi:10.1002/ana.410340312 · Cited by 219
Progressive brain atrophy on serial MRI in dementia with Lewy bodies, AD, and vascular dementia
O’Brien, J. T., Paling, S., Barber, R., Williams, E. D., Ballard, C., McKeith, I. G., Gholkar, A., Crum, W. R., Rossor, M. N., & Fox, N. C. (2001) · Neurology · doi:10.1212/wnl.56.10.1386 · Cited by 215
Self-citationAgeing: the cholinergic hypothesis of cognitive decline
Gallagher, M., & Colombo, P. J. (1995) · Current Opinion in Neurobiology · doi:10.1016/0959-4388(95)80022-0 · Cited by 212
Yu, Q.-S., Holloway, H. W., Utsuki, T., Brossi, A., & Greig, N. H. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980459s · Cited by 210
Lehmann, D. J., Johnston, C., & Smith, A. D. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.11.1933 · Cited by 198
Atack, J. R., Perry, E. K., Bonham, J. R., Candy, J. M., & Perry, R. H. (1986) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1986.tb02858.x · Cited by 194
Cholinesterases and the Pathology of Alzheimer Disease
Geula, C., & Mesulam, M. M. (1995) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199501002-00005 · Cited by 193
Kumar, V., Anand, R., Messina, J., Hartman, R., & Veach, J. (2000) · European Journal of Neurology · doi:10.1046/j.1468-1331.2000.00046.x · Cited by 159
Functional Disability in Alzheimer's Disease
Gauthier, S. G., GSlinas, I., & Gauthier, L. (1997) · International Psychogeriatrics · doi:10.1017/s1041610297004857 · Cited by 131
Cholinesterases within neurofibrillary tangles related to age and Alzheimer's disease
Mesulam, M. M., & Morán, M. A. (1987) · Annals of Neurology · doi:10.1002/ana.410220206 · Cited by 128
From Molecular Structure to Alzheimer Therapy
Giacobini, E. (1997) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.74.225 · Cited by 110
Long-term effects of rivastigmine in moderately severe Alzheimer's disease
Doraiswamy, P. M., Krishnan, K., Anand, R., Sohn, H., Danyluk, J., Hartman, R. D., & Veach, J. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00326-8 · Cited by 108
Molecular forms of acetylcholinesterase in subcortical areas of normal and Alzheimer disease brain
Siek, G. C., Katz, L. S., Fishman, E. B., Korosi, T. S., & Marquis, J. K. (1990) · Biological Psychiatry · doi:10.1016/0006-3223(90)90524-6 · Cited by 97
Pathological Proteins in Senile Plaques.
McGeer, P. L., Klegeris, A., Walker, D. G., Yasuhara, O., & McGeer, E. G. (1994) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.174.269 · Cited by 96
Wallin, A., Sjögren, M. J. C., Edman, Å., Blennow, K., & Regland, B. (2000) · European Neurology · doi:10.1159/000008242 · Cited by 94
Moretti, R., Torre, P., Antonello, R. M., & Cazzato, G. (2001) · European Journal of Neurology · doi:10.1046/j.1468-1331.2001.00224.x · Cited by 87
Yu, Q., Holloway, H. W., Flippen-Anderson, J. L., Hoffman, B., Brossi, A. R., & Greig, N. H. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010080x · Cited by 79
Wiebusch, H., Poirier, J., S�vigny, P., & Schappert, K. T. (1999) · Human Genetics · doi:10.1007/s004390050929 · Cited by 70
The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics
Greig, N. H., Micheli, E. D., Holloway, H. W., Yu, Q.-S., Utsuki, T., Perry, T., Ingram, D. K., Deutsch, J., Lahiri, D. K., & Soncrant, T. T. (2000) · Acta Neurologica Scandinavica · doi:10.1034/j.1600-0404.2000.00311.x · Cited by 70
O'Brien, J. T., & Ballard, C. G. (2001) · BMJ · doi:10.1136/bmj.323.7305.123 · Cited by 63
Self-citationGiacobini, E., DeSarno, P., Clark, B., & McIlhany, M. P. (1989) · Progress in brain research · doi:10.1016/s0079-6123(08)62493-0 · Cited by 62
Grubber, J. M., Saunders, A. M., Crane-Gatherum, A., Scott, W. K., Martin, E. R., Haynes, C. S., Conneally, P. M., Small, G. W., Roses, A. D., Haines, J. L., et al. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00426-7 · Cited by 36
The butyrylcholinesterase K variant is a protective factor for sporadic Alzheimer's disease in women
Alvarez-Arcaya, Combarros, O., Llorca, J., Sánchez-Guerra, M., Berciano, J., Fernández‐Viadero, C., & Peña, N. (2000) · Acta Neurologica Scandinavica · doi:10.1034/j.1600-0404.2000.102006350.x · Cited by 35
Nakamura, S., Takemura, M., Suenaga, T., Akiguchi, I., Kimura, J., Yasuhara, O., Kimura, T., & Kitaguchi, N. (1992) · Acta Neuropathologica · doi:10.1007/bf00227670 · Cited by 15
The effects of rivastigmine on behavioral symptoms in severe ad patients in a nursing home setting
Anand, R., Koumaras, B., & Hartman, R. D. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)83323-0 · Cited by 5
Cited by
Contributions of memory circuits to language: the declarative/procedural model
Ullman, M. T. (2004) · Cognition · doi:10.1016/j.cognition.2003.10.008 · Cited by 1,893
The significance of the cholinergic system in the brain during aging and in Alzheimer’s disease
Schliebs, R., & Arendt, T. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0579-2 · Cited by 530
Nachon, F., Carletti, E., Ronco, C., Trovaslet, M., Nicolet, Y., Jean, L., & Renard, P.-Y. (2013) · Biochemical Journal · doi:10.1042/bj20130013 · Cited by 478
Wilkinson, D. G., Francis, P. T., Schwam, E., & Payne-Parrish, J. (2004) · Drugs & Aging · doi:10.2165/00002512-200421070-00004 · Cited by 365
Yang, Z.-Z., Zhang, Y.-Q., Wang, Z.-Z., Wu, K., Lou, J.-N., & Qi, X.-R. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.05.009 · Cited by 248
Metadata
- Authors
- Ballard, C. G.
- Venue
- European Neurology
- Publisher
- S. Karger AG
- Published
- 2002
- Volume
- 47
- Issue
- 1
- Pages
- 64-70
- ISSN
- 0014-3022 (ISSN-L)
- 1421-9913
- OpenAlex
- W2019720355
- Cited by
- 260
- References
- 51
- FWCI
- 9.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.